Cell cycle activation by c‐myc in a Burkitt lymphoma model cell line

The product of the proto‐oncogene c‐myc (myc) is a potent activator of cell proliferation. In Burkitt lymphoma (BL), a human B‐cell tumor, myc is consistently found to be transcriptionally activated by chromosomal translocation. The mechanisms by which myc promotes cell cycle progression in B‐cells is not known. As a model for myc activation in BL cells, we have established a human EBV‐EBNA1 positive B‐cell line, P493‐6, in which myc is expressed under the control of a tetracycline regulated promoter. If the expression of myc is switched off, P493‐6 cells arrest in G0/G1 in the presence of serum. Re‐expression of myc activates the cell cycle without inducing apoptosis. myc triggers the expression of cyclin D2, cyclin E and Cdk4, followed by the activation of cyclin E‐associated kinase and hyper‐phosphorylation of Rb. The transcription factor E2F‐1 is expressed in proliferating and arrested cells at constant levels. The Cdk inhibitors p16, p21, p27 and p57 are expressed at low or not detectable levels in proliferating cells and are not induced after repression of myc. Ectopic expression of p16 inhibits cell cycle progression. These data suggest that myc triggers proliferation of P493‐6 cells by promoting the expression of a set of cell cycle activators but not by inactivating cell cycle inhibitors. Int. J. Cancer 87:787–793, 2000. © 2000 Wiley‐Liss, Inc.

[1]  J F Barrett,et al.  Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  U. Weidle,et al.  Control of cell growth by c-Myc in the absence of cell division , 1999, Current Biology.

[3]  W. Ansorge,et al.  Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 , 1999, The EMBO journal.

[4]  A. Sewing,et al.  Cyclins D1 and D2 mediate Myc‐induced proliferation via sequestration of p27Kip1 and p21Cip1 , 1999, The EMBO journal.

[5]  M. Cole,et al.  The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation , 1999, Oncogene.

[6]  B. Kempkes,et al.  The Proto-Oncogene c-myc Is a Direct Target Gene of Epstein-Barr Virus Nuclear Antigen 2 , 1999, Journal of Virology.

[7]  Kou-Juey Wu,et al.  Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. , 1999, Science.

[8]  R. Sutherland,et al.  c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry , 1998, Molecular and Cellular Biology.

[9]  J. Nevins,et al.  Toward an understanding of the functional complexity of the E2F and retinoblastoma families. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[10]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[11]  G. Hannon,et al.  Myc activates telomerase. , 1998, Genes & development.

[12]  B. Amati,et al.  Myc and the cell cycle. , 1998, Frontiers in bioscience : a journal and virtual library.

[13]  J. Sedivy,et al.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[14]  R. Bernards,et al.  Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity , 1997, Oncogene.

[15]  B. Amati,et al.  Cyclin E and c‐Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins , 1997, The EMBO journal.

[16]  M. Eilers,et al.  Activation of c-Myc uncouples DNA replication from activation of G1-cyclin-dependent kinases , 1997, Oncogene.

[17]  J. Bartek,et al.  Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4A as upstream regulators of Myc , 1997, Oncogene.

[18]  R A Jungmann,et al.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Andreas Sewing,et al.  Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes , 1997, Oncogene.

[20]  R. Eisenman,et al.  Myc target genes. , 1997, Trends in biochemical sciences.

[21]  I. Schieren,et al.  Effects of cyclin E overexpression on cell growth and response to transforming growth factor beta depend on cell context and p27Kip1 expression. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[22]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[23]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[24]  B. Amati,et al.  Growth arrest by the cyclin‐dependent kinase inhibitor p27Kip1 is abrogated by c‐Myc. , 1996, The EMBO journal.

[25]  B. Kempkes,et al.  c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Polymenis,et al.  An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc , 1996, Molecular and cellular biology.

[27]  D. Beach,et al.  Cdc25 cell-cycle phosphatase as a target of c-myc , 1996, Nature.

[28]  M. Henriksson,et al.  Proteins of the Myc network: essential regulators of cell growth and differentiation. , 1996, Advances in cancer research.

[29]  H. Hermeking,et al.  Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. , 1995, Oncogene.

[30]  M. Pagano,et al.  Identification of a Myc‐dependent step during the formation of active G1 cyclin‐cdk complexes. , 1995, The EMBO journal.

[31]  S. Sharma,et al.  Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. , 1995, Journal of immunology.

[32]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[33]  P. Farnham,et al.  An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants , 1995, Molecular and cellular biology.

[34]  E. Kremmer,et al.  B‐cell proliferation and induction of early G1‐regulating proteins by Epstein‐Barr virus mutants conditional for EBNA2. , 1995, The EMBO journal.

[35]  C. O'keefe,et al.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.

[36]  H. Hermeking,et al.  Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.

[37]  M. Gossen,et al.  Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. , 1994, Molecular and cellular biology.

[38]  S. Shurtleff,et al.  D-type cyclin-dependent kinase activity in mammalian cells , 1994, Molecular and cellular biology.

[39]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[40]  J. Nevins,et al.  Expression of transcription factor E2F1 induces quiescent cells to enter S phase , 1993, Nature.

[41]  J L Cleveland,et al.  The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  K. Isselbacher,et al.  Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Pagano,et al.  Differential modulation of cyclin gene expression by MYC. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  V. Rotter,et al.  c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[45]  E. Kremmer,et al.  The Epstein‐Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis‐element of the terminal protein 1 gene promoter. , 1993, The EMBO journal.

[46]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[48]  A. Polack,et al.  The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift. , 1991, Oncogene.

[49]  M. Groudine,et al.  Control of c-myc regulation in normal and neoplastic cells. , 1991, Advances in cancer research.

[50]  Didier Picard,et al.  Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells , 1989, Nature.